PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19434815-6	2009	CONCLUSIONS: Treatment with levamisole and colchicine can result in a significant reduction of serum IL-6, IL-8 or TNF-alpha level in MCBD patients.	Levamisole	28-38	C-X-C motif chemokine ligand 8	Homo sapiens	107-111	
25098981-0	2014	Assessment of serum interleukin-8 as a sensitive serological marker in monitoring the therapeutic effect of levamisole in recurrent aphthous ulcers: a randomized control study.	Levamisole	108-118	C-X-C motif chemokine ligand 8	Homo sapiens	20-33	
25098981-1	2014	AIM: The study was designed to evaluate the serum interleukin-8 (IL-8) levels in patients with recurrent aphthous ulcer (RAU) and monitor the immunomodulation and altered IL-8 levels by levamisole before therapy and after levamisole therapy.	Levamisole	186-196	C-X-C motif chemokine ligand 8	Homo sapiens	171-175	
25098981-8	2014	Highly significant comparisons were obtained in the serum IL-8 between study and control groups before the onset of levamisole (t = 6.53, P <= 0.001).	Levamisole	116-126	C-X-C motif chemokine ligand 8	Homo sapiens	58-62	
25098981-9	2014	IL-8 levels reduced by 72% after levamisole was instituted in RAU patients and comparison was highly significant for before and after levamisole onset (t = 5.54, P <= 0.001).	Levamisole	33-43	C-X-C motif chemokine ligand 8	Homo sapiens	0-4	
25098981-9	2014	IL-8 levels reduced by 72% after levamisole was instituted in RAU patients and comparison was highly significant for before and after levamisole onset (t = 5.54, P <= 0.001).	Levamisole	134-144	C-X-C motif chemokine ligand 8	Homo sapiens	0-4	
19434815-0	2009	Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet"s disease.	Levamisole	15-25	C-X-C motif chemokine ligand 8	Homo sapiens	88-92	
15948980-8	2005	In some OLP patients with the serum IL-6 or IL-8 levels higher than the upper limit of normal serum concentration, treatment with levamisole for a period of 0.5-6.0 months could significantly reduce the mean serum IL-6 level from 14.3 +/- 1.9 pg mL(-1) to 3.2 +/- 0.6 pg mL(-1) (P < 0.001) and could significantly reduce the mean serum IL-8 level from 95.8 +/- 17.1 pg mL(-1) to 14.8 +/- 5.8 pg mL(-1) (P < 0.001).	Levamisole	130-140	C-X-C motif chemokine ligand 8	Homo sapiens	44-48	
15948980-8	2005	In some OLP patients with the serum IL-6 or IL-8 levels higher than the upper limit of normal serum concentration, treatment with levamisole for a period of 0.5-6.0 months could significantly reduce the mean serum IL-6 level from 14.3 +/- 1.9 pg mL(-1) to 3.2 +/- 0.6 pg mL(-1) (P < 0.001) and could significantly reduce the mean serum IL-8 level from 95.8 +/- 17.1 pg mL(-1) to 14.8 +/- 5.8 pg mL(-1) (P < 0.001).	Levamisole	130-140	C-X-C motif chemokine ligand 8	Homo sapiens	339-343	
15948980-10	2005	Levamisole can modulate both the serum IL-6 and IL-8 levels in OLP patients.	Levamisole	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	48-52	
15948980-11	2005	IL-8, like IL-6, is also a useful serum marker in evaluating the therapeutic effects of levamisole on OLP patients.	Levamisole	88-98	C-X-C motif chemokine ligand 8	Homo sapiens	0-4	
15128054-10	2004	In 82 RAU patients with the serum IL-6 or IL-8 levels higher than the upper limit of normal serum concentration, treatment with levamisole for a period of 0.5-3.5 months could significantly reduce the serum IL-6 level from 12.0 +/- 1.6 to 3.0 +/- 0.5 pg/ml (P < 0.001), and could significantly lower the serum IL-8 level from 70.9 +/- 11.2 to 13.8 +/- 3.1 pg/ml (P < 0.001).	Levamisole	128-138	C-X-C motif chemokine ligand 8	Homo sapiens	42-46	
15128054-10	2004	In 82 RAU patients with the serum IL-6 or IL-8 levels higher than the upper limit of normal serum concentration, treatment with levamisole for a period of 0.5-3.5 months could significantly reduce the serum IL-6 level from 12.0 +/- 1.6 to 3.0 +/- 0.5 pg/ml (P < 0.001), and could significantly lower the serum IL-8 level from 70.9 +/- 11.2 to 13.8 +/- 3.1 pg/ml (P < 0.001).	Levamisole	128-138	C-X-C motif chemokine ligand 8	Homo sapiens	313-317	
15128054-12	2004	Levamisole can modulate both the serum IL-6 and IL-8 levels in RAU patients.	Levamisole	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	48-52	
15128054-13	2004	IL-8, like IL-6, is also a useful serum marker in evaluating therapeutic effects of levamisole on RAU patients.	Levamisole	84-94	C-X-C motif chemokine ligand 8	Homo sapiens	0-4